Arne Streitbuerger1,2, Marcel P Henrichs3, Gregor Hauschild1, Markus Nottrott1, Wiebke Guder1,2, Jendrik Hardes4,5. 1. Department of Orthopedics and Tumor Orthopedics, Münster University Hospital, Münster, Germany. 2. Department of Oncologic Musculoskeletal Surgery, Essen University Hospital, Hufelandstr. 55, 45147, Essen, Germany. 3. Department of Orthopedics, Paracelsus Clinic, Osnabrück, Germany. 4. Department of Orthopedics and Tumor Orthopedics, Münster University Hospital, Münster, Germany. jendrik.hardes@uk-essen.de. 5. Department of Oncologic Musculoskeletal Surgery, Essen University Hospital, Hufelandstr. 55, 45147, Essen, Germany. jendrik.hardes@uk-essen.de.
Abstract
BACKGROUND: Proximal femur replacements in patients with sarcoma are associated with high rates of infection. This study is the largest one comparing infection rates with titanium versus silver-coated megaprostheses in sarcoma patients. METHODS: Infection rates were assessed in 99 patients with proximal femur sarcoma who underwent placement of a titanium (n = 35) or silver-coated (n = 64) megaprosthesis. Treatments administered for infection were also analyzed. RESULTS: Infections occurred in 14.3% of patients in the titanium group, in comparison with 9.4% of those in the silver group, when the development of infection was the primary end point. The 5- and 10-year event-free survival rates for the prosthesis relative to the parameter of infection were 90% in the silver group and 83% in the titanium group. The overall infection rates were 10.9% in the silver group and 20% in the titanium group. Two patients each in the silver and titanium groups ultimately had to undergo amputation. The need for two-stage prosthesis exchanges (57.1% in the titanium group) declined to 14.3% in the silver group. CONCLUSION: Using a silver-coated proximal femoral replacement nearly halved the overall infection rate. When infections occurred, it was usually possible to avoid two-stage prosthesis exchanges in the silver group.
BACKGROUND: Proximal femur replacements in patients with sarcoma are associated with high rates of infection. This study is the largest one comparing infection rates with titanium versus silver-coated megaprostheses in sarcomapatients. METHODS:Infection rates were assessed in 99 patients with proximal femur sarcoma who underwent placement of a titanium (n = 35) or silver-coated (n = 64) megaprosthesis. Treatments administered for infection were also analyzed. RESULTS:Infections occurred in 14.3% of patients in the titanium group, in comparison with 9.4% of those in the silver group, when the development of infection was the primary end point. The 5- and 10-year event-free survival rates for the prosthesis relative to the parameter of infection were 90% in the silver group and 83% in the titanium group. The overall infection rates were 10.9% in the silver group and 20% in the titanium group. Two patients each in the silver and titanium groups ultimately had to undergo amputation. The need for two-stage prosthesis exchanges (57.1% in the titanium group) declined to 14.3% in the silver group. CONCLUSION: Using a silver-coated proximal femoral replacement nearly halved the overall infection rate. When infections occurred, it was usually possible to avoid two-stage prosthesis exchanges in the silver group.
Entities:
Keywords:
Bone neoplasms; Implantation; Prosthesis-related infections; Proximal femur; Sarcoma; Silver
Authors: Atul F Kamath; Kevin L Ong; Edmund Lau; Vanessa Chan; Thomas P Vail; Harry E Rubash; Daniel J Berry; Kevin J Bozic Journal: J Arthroplasty Date: 2015-03-31 Impact factor: 4.757
Authors: Philipp T Funovics; Christian Hipfl; Jochen G Hofstaetter; Stephan Puchner; Rainer I Kotz; Martin Dominkus Journal: Int Orthop Date: 2010-08-28 Impact factor: 3.075
Authors: M Glehr; A Leithner; J Friesenbichler; W Goessler; A Avian; D Andreou; W Maurer-Ertl; R Windhager; P-U Tunn Journal: Bone Joint J Date: 2013-07 Impact factor: 5.082
Authors: P J Dahlberg; W A Agger; J R Singer; W R Yutuc; K L Newcomer; A Schaper; B L Rooney Journal: Infect Control Hosp Epidemiol Date: 1995-09 Impact factor: 3.254
Authors: Gregor Hauschild; Jendrik Hardes; Georg Gosheger; Sandra Stoeppeler; Helmut Ahrens; Franziska Blaske; Christoph Wehe; Uwe Karst; Steffen Höll Journal: Biomed Res Int Date: 2015-01-28 Impact factor: 3.411
Authors: J Friesenbichler; M Bergovec; W Maurer-Ertl; P Reinbacher; M Maier; F Amerstorfer; A Leithner Journal: Orthopade Date: 2019-07 Impact factor: 1.087
Authors: Federico Sacchetti; Raphael Kilian; Francesco Muratori; Stephane Cherix; Lorenzo Foschi; Riccardo Morganti; Domenico Andrea Campanacci; Rodolfo Capanna Journal: Arch Bone Jt Surg Date: 2022-05
Authors: Christoph Theil; Jan Schwarze; Georg Gosheger; Burkhard Moellenbeck; Kristian Nikolaus Schneider; Niklas Deventer; Sebastian Klingebiel; George Grammatopoulos; Friedrich Boettner; Tom Schmidt-Braekling Journal: Cancers (Basel) Date: 2022-01-11 Impact factor: 6.639